ABERCROMBIE GEORGE B 4

4 · BIOCRYST PHARMACEUTICALS INC · Filed Sep 14, 2021

Form 4

Period: 2021-09-10

Director

Transactions

Exercise/Conversion
Common Stock
2021-09-10$1.71/sh+11,000$18,810→ 14,000 total
Exercise/Conversion
Automatic Stock Option Grant
2021-09-10−30,000→ 0 total
Exercise: $2.91From: 2020-05-29Exp: 2029-05-29→ Common Stock (30,000 underlying)
Exercise/Conversion
Common Stock
2021-09-10$2.91/sh+30,000$87,300→ 74,000 total
Exercise/Conversion
Automatic Stock Option Grant
2021-09-10−11,000→ 0 total
Exercise: $1.71From: 2013-06-30Exp: 2023-05-31→ Common Stock (11,000 underlying)
Exercise/Conversion
Common Stock
2021-09-10$3.22/sh+30,000$96,600→ 44,000 total
Exercise/Conversion
Automatic Stock Option Grant
2021-09-10−30,000→ 0 total
Exercise: $3.22From: 2016-06-23Exp: 2026-05-23→ Common Stock (30,000 underlying)
Sale
Common Stock
2021-09-10$15.09/sh−74,000$1,116,660→ 0 total

Footnotes (1)

[F1]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $14.87 to $15.31. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Documents

1 file